Kristina Burow
VCManaging Director, ARCH Venture Partners
Biotech company builder from bench science
Background
Kristina Burow is a Managing Director at ARCH Venture Partners who joined the firm in 2002 as an Associate. She focuses on creating and developing companies advancing transformative therapies, with deep expertise in oncology, neuroscience, and cell/gene therapy. She co-founded Neumora Therapeutics and Orbital Therapeutics (acquired by Bristol Myers-Squibb). Other major exits include Receptos (acquired by Celgene for $7.2 billion) and Vividion Therapeutics (acquired by Bayer). She holds an MBA from University of Chicago, an MA in Chemistry from Columbia, and a BS in Chemistry from UC Berkeley.
Investment Thesis
Company creation from breakthrough science in neuroscience, oncology, and cellular medicine, particularly first-in-class mechanisms.
Investment Focus
Stages
Sectors
Based in: Chicago, IL (North America)